Sanofi Loses Court Challenge to FDA Generic Lovenox Approval

Sanofi lost a challenge to the U.S. Food and Drug Administration’s approval for a generic version of Lovenox, the blood-thinning drug that had sales of $3.7 billion in 2010.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.